Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zhejiang Jingxin Pharmaceutical Co., Ltd.

Why is Zhejiang Jingxin Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 3.23% and Operating profit at 12.38% over the last 5 years

Negative results in Mar 25

OPERATING CASH FLOW(Y) Lowest at CNY 605.69 MM
INTEREST(Q) At CNY 1.72 MM has Grown at 255.63%
RAW MATERIAL COST(Y) Grown by 8.45% (YoY)

With ROE of 13.57%, it has a attractive valuation with a 2.36 Price to Book Value

Over the past year, while the stock has generated a return of 44.09%, its profits have risen by 9.1% ; the PEG ratio of the company is 1.9
At the current price, the company has a high dividend yield of 1.8

Market Beating Performance

The stock has generated a return of 44.09% in the last 1 year, much higher than market (China Shanghai Composite) returns of 15.18%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Zhejiang Jingxin Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zhejiang Jingxin Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Zhejiang Jingxin Pharmaceutical Co., Ltd.

-100.0%

1.64

40.11%

China Shanghai Composite

15.19%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.23%

EBIT Growth (5y)

12.38%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.05

Sales to Capital Employed (avg)

0.64

Tax Ratio

14.81%

Dividend Payout Ratio

42.33%

Pledged Shares

Institutional Holding

ROCE (avg)

15.55%

ROE (avg)

12.57%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.36

EV to EBIT

17.46

EV to EBITDA

11.92

EV to Capital Employed

2.48

EV to Sales

3.14

PEG Ratio

1.92

Dividend Yield

1.78%

ROCE (Latest)

14.20%

ROE (Latest)

13.57%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-14What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 605.69 MM

INTEREST(Q)

At CNY 1.72 MM has Grown at 255.63%

RAW MATERIAL COST(Y)

Grown by 8.45% (YoY

CASH AND EQV(HY)

Lowest at CNY 1,876.8 MM

DEBT-EQUITY RATIO (HY)

Highest at -4.49 %

NET SALES(Q)

At CNY 945.98 MM has Fallen at -7.9%

OPERATING PROFIT(Q)

Lowest at CNY 160.97 MM

PRE-TAX PROFIT(Q)

Lowest at CNY 193.15 MM

NET PROFIT(Q)

Lowest at CNY 163.23 MM

Here's what is not working for Zhejiang Jingxin Pharmaceutical Co., Ltd.

Operating Cash Flow

Lowest at CNY 605.69 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

At CNY 1.72 MM has Grown at 255.63%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

At CNY 945.98 MM has Fallen at -7.9%

over average net sales of the previous four periods of CNY 1,027.17 MM

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY 160.97 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Pre-Tax Profit

Lowest at CNY 193.15 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

Lowest at CNY 163.23 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

Cash and Eqv

Lowest at CNY 1,876.8 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -4.49 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 8.45% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales